Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
8
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales132,186Millions of yenYear on year +8.0%Progress 97.2%
Operating profit3,313Millions of yenYear on year +5.0%Progress 110.4%
Ordinary income3,193Millions of yenYear on year +1.0%Progress 118.3%
Net income attributable to owners of the parent1,070Millions of yenYear on year -15.2%Progress 107.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥36.64
Operating Margin2.5%
Financial position at period-end
Total assets80,100Millions of yen
of which net assets 17,413 Millions of yenEquity ratio 21.6%vs. prior year-end -1.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-3,441
Investment-4,036
Financials+6,789
Net change-688
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period7,743 Millions of yen
Segment revenue
Community Pharmacy Network Business127,18095.5%
Rental and Facilities-Related Business3,3802.5%
Food-service contract business2,2891.7%
Other businesses3360.3%
Segment profit
Community Pharmacy Network Business6,025
Rental and Facilities-Related Business155
Food-service contract business-18
Other businesses-22
Outlook and shareholder returns
Full-year earnings forecast
Net Sales136,000 Millions of yen (YoY +2.9%)
Operating profit3,000 Millions of yen (YoY -9.4%)
Ordinary income2,700 Millions of yen (YoY -15.4%)
Net income1,000 Millions of yen (YoY -6.6%)
Annual Dividend Forecast¥12 per share → ¥12 per share（0.0%）
Payout ratio32.7
Factors Behind Changes in Business Performance
Revenue and operating profit increased due to higher personnel expenses resulting from wage increases and other factors, and a decline in prescription volumes at existing stores in the regional pharmacy division, mainly due to a decrease in patients with acute conditions, was more than offset by an increase in new members in the pharmaceutical network division and improved profitability in the pharmaceutical logistics division, which began operations in the previous fiscal year.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 3 / Company name 株式会社クライマー, 有限会社メディコプランニング, 株式会社アカマル / Excluded Number of companies 5 / Company name 株式会社永冨調剤薬局, 株式会社鶴丸調剤薬局, 株式会社白十字総合薬局, 有限会社メディコプランニング, 株式会社アカマル
Material subsequent eventsNot applicable.
Impairment loss529 Millions of yen
Breakdown of extraordinary income (loss)Category Extraordinary gains / Item Gain on sale of non-current assets / Amount 16 Millions of yen, Category Extraordinary gains / Item Gain on business transfer / Amount 8 Millions of yen, Category Extraordinary gains / Item Other / Amount 2 Millions of yen, Category Extraordinary Losses / Item Loss on sale of fixed assets / Amount 5 Millions of yen, Category Extraordinary Losses / Item Loss on Disposal of Fixed Assets / Amount 35 Millions of yen, Category Extraordinary Losses / Item Impairment Losses / Amount 529 Millions of yen, Category Extraordinary Losses / Item Loss on closure of stores / Amount 94 Millions of yen, Category Extraordinary Losses / Item Other / Amount 4 Millions of yen
Depreciation and amortization2,438 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End30,642,600
Treasury Shares at Period-End1,414,124
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | 132,186 Millions of yen (YoY +8.0%) |
| Operating profit | 3,313 Millions of yen (YoY +5.0%) |
| Ordinary income | 3,193 Millions of yen (YoY +1.0%) |
| Profit attributable to owners of the parent | 1,070 Millions of yen (YoY -15.2%) |
| Net income per share | ¥36.64 |
| Operating Margin | 2.5% |
| Equity ratio | End of the current fiscal period 21.6 / End of previous period 23 |
| Total assets | 80,100 Millions of yen |
| Net assets | 17,413 Millions of yen |
| Cash flows from operating activities | -3,441 Millions of yen |
| Cash flows from investing activities | -4,036 Millions of yen |
| Cash flows from financing activities | 6,789 Millions of yen |
| Cash and cash equivalents at end of period | 7,743 Millions of yen |
| Full-year earnings forecast | Net Sales 136,000 Millions of yen (YoY +2.9%) / Operating profit 3,000 Millions of yen (YoY -9.4%) / Ordinary income 2,700 Millions of yen (YoY -15.4%) / Net income 1,000 Millions of yen (YoY -6.6%) |
| Annual Dividend Forecast | ¥12 per share → ¥12 per share（0.0%） |
| Payout ratio | 32.7 |
| Segment revenue | Segment Community Pharmacy Network Business / Net Sales 127,180 Millions of yen / yoy_pct 8.7 Millions of yen, Segment Rental and Facilities-Related Business / Net Sales 3,380 Millions of yen / yoy_pct -2.6 Millions of yen, Segment Food-service contract business / Net Sales 2,289 Millions of yen / yoy_pct -3 Millions of yen, Segment Other businesses / Net Sales 336 Millions of yen / yoy_pct -1.8 Millions of yen |
| Segment profit | Segment Community Pharmacy Network Business / Segment profit 6,025 Millions of yen / yoy_pct 7.1 Millions of yen, Segment Rental and Facilities-Related Business / Segment profit 155 Millions of yen / yoy_pct -18.3 Millions of yen, Segment Food-service contract business / Segment profit -18 Millions of yen / yoy_pct Not disclosed / Prior-year period Operating profit of ¥10 million, Segment Other businesses / Segment profit -22 Millions of yen / yoy_pct Not disclosed / Prior-year period Operating loss of ¥29 million |
| Depreciation and amortization | 2,438 Millions of yen |
| Impairment loss | 529 Millions of yen |
| Breakdown of extraordinary income (loss) | Category Extraordinary gains / Item Gain on sale of non-current assets / Amount 16 Millions of yen, Category Extraordinary gains / Item Gain on business transfer / Amount 8 Millions of yen, Category Extraordinary gains / Item Other / Amount 2 Millions of yen, Category Extraordinary Losses / Item Loss on sale of fixed assets / Amount 5 Millions of yen, Category Extraordinary Losses / Item Loss on Disposal of Fixed Assets / Amount 35 Millions of yen, Category Extraordinary Losses / Item Impairment Losses / Amount 529 Millions of yen, Category Extraordinary Losses / Item Loss on closure of stores / Amount 94 Millions of yen, Category Extraordinary Losses / Item Other / Amount 4 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 3 / Company name 株式会社クライマー, 有限会社メディコプランニング, 株式会社アカマル / Excluded Number of companies 5 / Company name 株式会社永冨調剤薬局, 株式会社鶴丸調剤薬局, 株式会社白十字総合薬局, 有限会社メディコプランニング, 株式会社アカマル |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 30,642,600 |
| Treasury Shares at Period-End | 1,414,124 |
| Factors Behind Changes in Business Performance | Revenue and operating profit increased due to higher personnel expenses resulting from wage increases and other factors, and a decline in prescription volumes at existing stores in the regional pharmacy division, mainly due to a decrease in patients with acute conditions, was more than offset by an increase in new members in the pharmaceutical network division and improved profitability in the pharmaceutical logistics division, which began operations in the previous fiscal year. |
Items this document does not state (4)
Revision to Earnings ForecastShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and operating profit increased despite higher personnel expenses and a decline in prescription volumes at existing stores in the regional pharmacy division, supported by an increase in new members in the pharmaceutical network division and improved profitability in the pharmaceutical logistics division. For the next fiscal year, the Company expects an increase in one-time expenses associated with the integration of its data infrastructure to centralize customer data management.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.